Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $60.00 (from $45.00) while maintaining an Outperform rating.
The analyst commented, "BioHaven is executing on Nurtec's introduction, and despite the pandemic impact, the initial prescription figures for the first 6 weeks on market are already well ahead of our expectations. With what should be a continued successful acute indication launch, this is setting the stage for the broader and more differentiated prophylaxis indication, which is on track for a 2021 introduction. Add."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Raised to INR1,220 at Kotak
- Hindustan Petroleum (HPCL:IN) PT Lowered to INR350 at Kotak
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
